Education
About Us
Working with TipRanks
Follow Us
Immuron Limited (DE:ANW)
FRANKFURT:ANW
ANW Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.66M
Enterprise Value€5.02M
Total Cash (Recent Filing)€5.87M
Total Debt (Recent Filing)€117.13K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 04, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding326,653,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Product Plus Clinical PipelineHaving a marketed product (Travelan) plus clinical-stage assets provides durable commercial runway and development optionality. Travelan validates go-to-market capability and distributor relationships, while IMM-124E offers long-term upside if clinical development and approvals succeed.
Positive Revenue GrowthSustained top-line growth signals underlying demand and market traction for the company’s oral immunotherapies. Over a 2-6 month horizon this trend supports scaling potential, improves negotiating leverage with partners and distributors, and helps absorb fixed R&D and commercial costs.
Low Leverage / Conservative Balance SheetVery low debt provides durable financial flexibility for a biotech with development needs. It reduces insolvency risk, lowers fixed financing costs, and preserves optionality to raise capital or strike partnerships without immediate solvency pressure during multi-stage clinical programs.
Bears Say
Ongoing Lack Of ProfitabilityPersistent negative net profit and EBIT margins reflect structural operational deficits. Without margin improvement or substantial revenue scaling, the company will require recurrent financing to fund operations and trials, which can dilute shareholders and strain long-term sustainability.
Negative Operating And Free Cash FlowConsistently negative operating and free cash flow limit the firm’s ability to self-fund clinical development and commercial expansion. This structural cash shortfall increases reliance on external funding, which can delay programs or impose unfavorable terms that impair strategic flexibility.
Weak Returns On Invested CapitalA negative ROE signals that deployed capital is not producing shareholder returns, pointing to inefficiencies in commercialization or R&D allocation. Over months this undermines investor confidence and suggests management must either improve execution or redirect capital to higher-return uses.
Immuron Limited News
ANW FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is €5.66M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Mar 04, 2026 which is in 8 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Sep 02, 2025. The company reported €0 earnings per share for the quarter, the consensus estimate of N/A by €0.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is 0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 326,653,600 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of €0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in DE:ANW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuron Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.31%
12-Months-Change
Fundamentals
Return on Equity
-49.96%
Trailing 12-Months
Asset Growth
-41.64%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―